MARKET

ORTX

ORTX

Orchard Therapeutics plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.37
-0.32
-3.30%
Closed 16:00 05/28 EDT
OPEN
9.67
PREV CLOSE
9.69
HIGH
9.79
LOW
9.25
VOLUME
404.98K
TURNOVER
--
52 WEEK HIGH
19.23
52 WEEK LOW
5.17
MARKET CAP
911.36M
P/E (TTM)
-6.2296
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ORTX stock price target is 21.67 with a high estimate of 29.00 and a low estimate of 15.00.

EPS

ORTX News

More
Orchard Therapeutics to Present at Virtual Investor Conferences in June
GlobeNewswire · 1d ago
UPDATE: Orchard Therapeutics Says 1-Year Follow-Up Results For OTL-203, Initiation Of Registrational Trial Expected In 2021
Benzinga · 05/15 10:03
Orchard Therapeutics Reports New Interim Data From OTL-203 Proof-Of-Concept Study For MPS-I: 'Improved Motor Skills, Stable Cognitive Scores and Normal Growth Seen in First Two Patients'
Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex
Benzinga · 05/15 10:03
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy in devel
GlobeNewswire · 05/15 10:00
Orchard Therapeutics: A Leading Gene Therapy Company For Your Watchlist
Seeking Alpha - Article · 05/11 19:11
Orchard Therapeutics (ORTX) Q1 2020 Earnings Call Transcript
Motley Fool · 05/09 21:00
Orchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 07:36
84 Biggest Movers From Yesterday
Gainers Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) shares climbed 78.6% to close at $2.42 on Thursday after falling 10% on Wednesday.
Benzinga · 05/08 09:34

Industry

Pharmaceuticals
+1.28%
Pharmaceuticals & Medical Research
+1.04%

Hot Stocks

Symbol
Price
%Change

About ORTX

Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.
More

Webull offers kinds of Orchard Therapeutics PLC - ADR stock information, including NASDAQ:ORTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORTX stock news, and many more online research tools to help you make informed decisions.